Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003467 · ClinicalTrials.gov registry record · Phase 2
Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT00003467 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 68 participants.
The verdict
NCT00003467, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carmustine in treating adults with recurrent supratentorial low-grade glioma.
Interventions
- DRUG carmustine
- PROCEDURE surgical procedure
- DRUG polifeprosan 20 with carmustine implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 1998-01 |
| Est. Completion | 2004-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003467
The ClinicalTrials.gov registry entry for NCT00003467 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carmustine is the first listed.
NCT00003467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003467 about?
NCT00003467 is a clinical study titled "Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carmustine in treating adults with recurrent supratentorial low-grade glioma.
What is the current status of trial NCT00003467?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 1998-01. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00003467?
The interventions under investigation include: carmustine (DRUG), surgical procedure (PROCEDURE), polifeprosan 20 with carmustine implant (DRUG).
Who is sponsoring clinical trial NCT00003467?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.